IMTX
Price
$4.35
Change
+$0.01 (+0.23%)
Updated
May 9, 02:32 PM (EDT)
Capitalization
527.53M
11 days until earnings call
SYRE
Price
$12.86
Change
+$0.15 (+1.18%)
Updated
May 8 closing price
Capitalization
775.14M
83 days until earnings call
Ad is loading...

IMTX vs SYRE

Header iconIMTX vs SYRE Comparison
Open Charts IMTX vs SYREBanner chart's image
Immatics
Price$4.35
Change+$0.01 (+0.23%)
Volume$1.35K
Capitalization527.53M
Spyre Therapeutics
Price$12.86
Change+$0.15 (+1.18%)
Volume$322.54K
Capitalization775.14M
IMTX vs SYRE Comparison Chart
Loading...
IMTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMTX vs. SYRE commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMTX is a StrongBuy and SYRE is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (IMTX: $4.34 vs. SYRE: $12.86)
Brand notoriety: IMTX and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMTX: 72% vs. SYRE: 45%
Market capitalization -- IMTX: $527.53M vs. SYRE: $775.14M
IMTX [@Biotechnology] is valued at $527.53M. SYRE’s [@Biotechnology] market capitalization is $775.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMTX’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • IMTX’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, IMTX is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMTX’s TA Score shows that 3 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • IMTX’s TA Score: 3 bullish, 7 bearish.
  • SYRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than IMTX.

Price Growth

IMTX (@Biotechnology) experienced а -13.37% price change this week, while SYRE (@Biotechnology) price change was -12.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.07%. For the same industry, the average monthly price growth was +11.11%, and the average quarterly price growth was -13.36%.

Reported Earning Dates

IMTX is expected to report earnings on Aug 12, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-5.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($775M) has a higher market cap than IMTX($528M). IMTX has higher P/E ratio than SYRE: IMTX (28.96) vs SYRE (1.72). IMTX YTD gains are higher at: -38.959 vs. SYRE (-44.759). IMTX has higher annual earnings (EBITDA): -36.26M vs. SYRE (-208.57M). SYRE has more cash in the bank: 603M vs. IMTX (491M). SYRE has less debt than IMTX: SYRE (0) vs IMTX (16M). IMTX has higher revenues than SYRE: IMTX (116M) vs SYRE (0).
IMTXSYREIMTX / SYRE
Capitalization528M775M68%
EBITDA-36.26M-208.57M17%
Gain YTD-38.959-44.75987%
P/E Ratio28.961.721,688%
Revenue116M0-
Total Cash491M603M81%
Total Debt16M0-
FUNDAMENTALS RATINGS
IMTX vs SYRE: Fundamental Ratings
IMTX
SYRE
OUTLOOK RATING
1..100
715
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8694
PRICE GROWTH RATING
1..100
6365
P/E GROWTH RATING
1..100
5577
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMTX's Valuation (66) in the null industry is in the same range as SYRE (76) in the Pharmaceuticals Major industry. This means that IMTX’s stock grew similarly to SYRE’s over the last 12 months.

IMTX's Profit vs Risk Rating (100) in the null industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that IMTX’s stock grew similarly to SYRE’s over the last 12 months.

IMTX's SMR Rating (86) in the null industry is in the same range as SYRE (94) in the Pharmaceuticals Major industry. This means that IMTX’s stock grew similarly to SYRE’s over the last 12 months.

IMTX's Price Growth Rating (63) in the null industry is in the same range as SYRE (65) in the Pharmaceuticals Major industry. This means that IMTX’s stock grew similarly to SYRE’s over the last 12 months.

IMTX's P/E Growth Rating (55) in the null industry is in the same range as SYRE (77) in the Pharmaceuticals Major industry. This means that IMTX’s stock grew similarly to SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMTXSYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 8 days ago
76%
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
IMTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIVOX12.05N/A
N/A
Fidelity Advisor International Value C
EQPGX21.92N/A
N/A
Fidelity Advisor Equity Growth I
CGRYX31.97N/A
N/A
Invesco Comstock Select Y
PIEFX16.59N/A
N/A
Federated Hermes Emerging Markets Eq IS
CRVRX8.08-0.03
-0.37%
NYLI CBRE Real Estate Fund Investor Cl

IMTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with RCKT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMTX
1D Price
Change %
IMTX100%
-1.14%
RCKT - IMTX
45%
Loosely correlated
+11.57%
MRUS - IMTX
44%
Loosely correlated
+8.47%
SYRE - IMTX
43%
Loosely correlated
+1.18%
CGON - IMTX
42%
Loosely correlated
+8.01%
ROIV - IMTX
42%
Loosely correlated
-1.25%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with BEAM. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+1.18%
BEAM - SYRE
56%
Loosely correlated
+6.32%
APGE - SYRE
52%
Loosely correlated
+7.29%
IDYA - SYRE
52%
Loosely correlated
+1.96%
CGON - SYRE
52%
Loosely correlated
+8.01%
RCKT - SYRE
50%
Loosely correlated
+11.57%
More